Chicago, IL - 2015 ASCO Annual Meeting - Howard M. Sandler, MD, presenting abstract LBA5002, A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT vs AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521). during Genitourinary (Prostate) Cancer Oral Abstract Session at the American Society of Clinical Oncology (ASCO) Annual Meeting here today, Sunday, May 31, 2015. Over 30,000 physicians, researchers and healthcare professionals from over 100 countries are attending the 51st Annual Meeting which is being held at the McCormick Place convention center. The Annual Meeting highlights the latest findings in all major areas of oncology from basic through clinical and epidemiological studies. Photo by © ASCO/David Eulitt 2015 Technical Questions: todd@toddbuchanan.com; ASCO Contact: photos@asco.org
Chicago, IL - 2015 ASCO Annual Meeting - General views at the American Society of Clinical Oncology (ASCO) Annual Meeting here today, Sunday, May 31, 2015. Over 30,000 physicians, researchers and healthcare professionals from over 100 countries are attending the 51st Annual Meeting which is being held at the McCormick Place convention center. The Annual Meeting highlights the latest findings in all major areas of oncology from basic through clinical and epidemiological studies. Photo by © ASCO/David Eulitt 2015 Technical Questions: todd@toddbuchanan.com; ASCO Contact: photos@asco.org
